A complex of the TSH receptor extracellular domain (amino acids 22-260; TSHR260) bound to a blocking-type human monoclonal autoantibody (K1-70) was purified, crystallised and the structure solved at 1 . 9 Å resolution. complexes show a root mean square deviation on all C a atoms of only 0 . 51 Å . These high-resolution crystal structures provide a foundation for developing new strategies to understand and control TSHR activation and the autoimmune response to the TSHR.
Introduction
The TSH receptor (TSHR) is a major autoantigen in autoimmune thyroid disease, and TSHR autoantibodies with thyroid-stimulating (agonist) activity are responsible for the hyperthyroidism of Graves' disease (Rees Smith et al. 1988 , Rapoport et al. 1998 , Sanders et al. 1997 . However, in rare cases, TSHR autoantibodies act as antagonists and prevent the TSHR-binding and stimulating activities of TSH and can cause hypothyroidism (Rees Smith et al. 1988 , McKenzie & Zakarija 1992 , Sanders et al. 1997 , Rapoport et al. 1998 . The availability of human monoclonal antibodies to the TSHR with the characteristics of patient serum autoantibodies has allowed major developments in our understanding of the TSHR-autoantibody interaction, and in the case of thyroid-stimulating autoantibodies, the crystal structure of a human monoclonal autoantibody (M22) in complex with the TSHR (amino acids 22-260; TSHR260) has been determined at 2 . 55 Å resolution (Sanders et al. 2007a) .
Recently, we have isolated two new human monoclonal autoantibodies to the TSHR from a single sample of a patient's peripheral blood lymphocytes , Evans et al. 2010 . One monoclonal antibody is a powerful thyroid stimulator (K1-18), and the other (K1-70) blocks the stimulating activities of TSH and TSHR autoantibodies (including M22 and K1-18) . We now describe the crystal structure of K1-70 Fab unbound (solved at 2 . 22 Å ) and the crystal structure of K1-70 Fab bound to TSHR260 (solved at 1 . 9 Å ). Using the information obtained from the crystal structures, we then carried out a molecular level analysis of the antigen-binding surfaces of K1-70 (antagonist) and M22 (agonist) Fabs as well as a detailed comparison of the interactions of K1-70 and M22 with the TSHR.
Materials and methods
Preparation of K1-70 Fab for crystallisation K1-70 IgG was prepared from heterohybridoma culture supernatants using protein A affinity chromatography on MabSelect (GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions. The purified IgG was treated with mercuripapain K1-70 Fab crystals were grown using the hanging drop vapour diffusion method with the structure screen 1 sparse matrix screen from Molecular Dimensions Ltd (Soham, UK). Condition 24 (30% PEG 400, 0 . 1 M sodium HEPES, 0 . 2 M magnesium chloride, pH 7 . 5) yielded single crystals suitable for X-ray diffraction data collection. A single crystal of dimensions 0 . 3!0 . 2 !0 . 2 mm was flash cooled in liquid nitrogen. X-ray diffraction data collections were performed at cryogenic temperatures. The dataset was collected using a Rigaku-007HF generator and an R-Axis IV image plate detector, and was indexed, integrated and scaled using MOSFLM and SCALA (Biofocus, Saffron Walden, UK).
The structure of K1-70 Fab was determined by the molecular replacement method using the pdb coordinates of 1LIL (V L and C L domains), 2BOS (V H domain) and 2EH7 (V L domain). Molecular replacement was performed using the program PHASER, and the resulting model given ten cycles of atomic refinement with tight geometric weights using REFMAC5 (Collaborative Computational Project number 4[CCP4] 1994). Electron density maps calculated after initial refinement were examined using COOT (Emsley et al. 2010) and automatically corrected and rebuilt using BUCCANEER (CCP4 1994) . The structural geometry of K1-70 Fab was checked using PROCHECK (Laskowski et al. 1993 , CCP4 1994 and RAMPAGE (CCP4 1994) . Electrostatic potential surfaces of the antigen-binding sites were generated using PYMOL (DeLano 2002) .
Preparation of the TSHR260-K1-70 Fab complex
A TSHR260 construct (coding for amino acids (aa) 1-260 of the human TSHR [764aas]) was produced and expressed in insect cells using the baculovirus system as described previously (Sanders et al. 2007a) . Purified K1-70 Fab was added to High Five insect cell cultures 96 h post infection to a final concentration of 2 mg/ml. Culture supernatants containing TSHR260-K1-70 Fab complex were harvested 120 h post infection by centrifugation at 500 g for 10 min. One tablet of complete protease inhibitors (Roche Diagnostics, Lewes, UK) was added per 200 ml supernatant, before storing at K70 8C until purification.
Purification of TSHR260-K1-70 Fab complex
Culture supernatant containing the TSHR260-K1-70
Fab complex was adjusted to pH 6 . 4 with 500 mmol/l NaH 2 PO 4 and loaded onto 75 ml Streamline Direct HST-1 matrix in a Streamline 25 expanded bed chromatography system (GE Healthcare), washed in 100 mmol/l NaCl and 50 mmol/l Tris-HCl (buffer A) pH 6 . 0, and then in buffer A pH 6 . 5 and eluted in buffer A pH 8 . 5 . The presence of the TSHR260-K1-70 Fab complex in the eluted fractions was confirmed by western blot analysis using a mouse monoclonal antibody (1 mg/ml) reactive with a TSHR epitope within amino acids 246-260 (TSHR MAb 18C5; Jeffreys et al. 2002) .
The TSHR260-K1-70 Fab complex was further purified by affinity chromatography using a mouse monoclonal antibody (TSHR MAb 14C4; Jeffreys et al. 2002 ) that binds to a conformational epitope within amino acids 22-261 of the TSHR extracellular domain coupled to CNBr-activated sepharose-4B (SigmaAldrich). The dialysed complex was then further purified using nickel affinity chromatography on an Ni-NTA agarose column (Qiagen, Crawley, UK). The complex was eluted with 80 mmol/l imidazole, 100 mmol/l NaCl and 50 mmol/l Tris-HCl (pH 8 . 0), dialysed into 100 mmol/l NaCl, 50 mmol/l Tris-HCl (pH 8 . 0) and used to set up deglycosylation reactions.
Deglycosylation of the TSHR260-K1-70 Fab complex
The purified complex was deglycosylated using Endoglycosidase F3 (Sigma-Aldrich) at an enzymeto-complex ratio of 152 mU of enzyme per mg of complex in 50 mmol/l sodium acetate buffer (pH 4 . 5) at 20 8C for 5 days. The deglycosylation reactions were then adjusted to pH 6 . 5 using 200 mmol/l Tris-HCl, run onto a cation exchange HPLC Bioassist S column (Tosoh) using an Akta (GE Healthcare) platform. The complex was eluted using a pH gradient from 6 . 5 to 9 . 0.
Eluted complex was further purified by size-exclusion chromatography. TSHR260-K1-70 Fab preparations were applied to a Superdex 200 XK-26 preparative column in 150 mmol/l NaCl and 10 mmol/l Tris-HCl (pH 7 . 6), and purified complex eluted from the P SANDERS and others . TSHR complex with blocking autoantibody column was adjusted to 20 mmol/l Tris-HCl and 25 mmol/l NaCl, pH 7 . 6. The complex was concentrated using an iCON concentrator (7 ml 9K MWCO; ThermoFisher) followed by a MicroCon YM-10 concentrator (Millipore, Watford, UK) to a final concentration of 10 mg/ml. X-ray diffraction and structure determination of TSHR260-K1-70 Fab
Crystals of TSHR260-K1-70 Fab complex were obtained in 96-well plates using the PEG/Ion HT screen from Hampton Research (Aliso Viejo, CA, USA). The best conditions were optimised further in 24-well plates using a range of PEG 3350 concentration from 16 to 26%, and the best crystals grew in 16% PEG 3350, 0 . 2 M sodium malonate, pH 5 . 0. A single crystal (dimensions 0 . 3!0 . 1 !0 . 1 mm) was transferred to a solution containing 22% PEG 3350, 0 . 2 M sodium malonate, pH 5 . 0, and flash frozen in liquid nitrogen. The dataset was collected on a Rigaku-007HF generator and an R-Axis IV image plate detector, and was indexed, integrated and scaled using MOSFILM and SCALA (Biofocus).
The unbound K1-70 Fab crystal structure and the TSHR260 crystal structure (Sanders et al. 2007a) were used for molecular replacement using the programs PHASER and REFMAC5 (CCP4 1994). Structural geometry was checked using PROCHECK and RAM-PAGE (CCP4 1994). Electrostatic potential surfaces were generated using PYMOL (DeLano 2002) . The TSHR-K1-70 structure has been deposited in the Protein Data Bank with accession number 2XWT.
Preparation of recombinant K1-70 Fab
The K1-70 heavy-chain (HC) RT-PCR product and the light-chain (LC) RT-PCR product with 'C' terminal six histidine tags were cloned into the Immunozap H/L vector (Stratagene Europe, Amsterdam, The Netherlands) into XhoI and SpeI, and SacI and XbaI restriction sites respectively (Sanders et al. 2004) . Specific 'forward' and 'reverse' primers were designed to change the K1-70 nucleotide sequence to code for the appropriate amino acid mutation (Sanders et al. 2007b) . Amino acid mutations in the K1-70 Fab HC or LC sequence were introduced using the Qwikchange Mutagenesis Kit (Stratagene) following the manufacturer's instructions. The presence of the wild-type or mutated HC or LC was verified by sequence analysis (Source BioScience, Cambridge, UK).
Plasmid DNA containing the K1-70 HC and LC sequences was transformed into HB2151 cells (GE Healthcare), and expression of recombinant Fab was induced in the presence of 1 mmol/l isopropyl-b-D galactoside and 0 . 3 mol/l sucrose. Expression of recombinant Fab was verified using western blot analysis (Birk & Koepsell 1987) with an anti-human IgG (Fab specific) antibody (SAFC, Poole, UK). Fabs were dialysed into PBS containing 0 . 2 g/l sodium azide and stored at K70 8C.
Briefly, 4 l supernatant containing K1-70 recombinant Fab (K1-70 rFab) were adjusted to pH 6 . 0 with 500 mmol/l sodium dihydrogen phosphate (pH 4 . 0) and loaded onto a 75 ml Streamline TM Direct HST-1 column (GE Healthcare). K1-70 rFab was eluted with 0 . 3 mol/l NaCl and 10 mmol/l Tris-HCl (pH 8 . 5) and finally purified by chromatography on an Ni-NTA agarose column (Qiagen). The purity of the eluted rFab was O95% as assessed by SDS-PAGE (Laemmli 1970) , and the concentration of the K1-70 rFab was calculated from the absorbance at 280 nm on the basis that 1 absorbance unit is equivalent to 0 . 7 mg/ml Fab.
Culture supernatants containing non-mutated (wild type; WT) or mutated K1-70 rFab were quantified using the Pierce Easy-Titer Human IgG (HCL) assay kit (ThermoFisher) against a standard curve of purified K1-70 rFab as per the manufacturer's instructions.
Inhibition of TSH-biotin binding to the TSHR by wild-type and mutated K1-70 rFabs
The ability of WT and mutated K1-70 rFabs to inhibit TSH-biotin binding to TSHR-coated ELISA plate wells was determined as described previously (RSR Ltd; Bolton et al. 1999) . A calibration curve prepared from purified rK1-70 Fab was included in each assay.
Briefly, 75 ml culture supernatant containing either WT or mutated rFab were diluted in 50 mmol/l NaCl, 20 mmol/l Tris-HCl, pH 7 . 8, 1% Triton X-100 and 1 mg/ml BSA, and after addition of 75 ml start buffer incubated in TSHR-coated wells at room temperature for 2 h with shaking, the assay was carried out as per the kit instructions. Inhibition of TSH-biotin binding was calculated as follows:
OD450 in the presence of test material OD450 in the presence of control material concentration) in cAMP assay buffer (NaCl-free Hank's Balanced Salt Solution containing 1 g/l glucose, 20 mmol/l HEPES, 222 mmol/l sucrose, 15 g/l BSA and 0 . 5 mmol/l 3-isobutyl-1-methylxanthine, pH 7 . 4) in the presence of 3 ng/ml pTSH were added, and cells were incubated at 37 8C in an atmosphere of 5% CO 2 in air for 1 h. After removal of test solutions, cells were lysed by the addition of 0 . 1 mol/l HCl, 1% Triton X-100, and the cAMP concentration in the lysates was determined using the Direct Cyclic AMP Correlate EIA kit (Assay Designs, Inc., Ann Arbor, MI, USA).
In a separate series of experiments, the effect of native K1-70 Fab on pTSH-mediated cAMP production was tested using Flp-In CHO cells expressing mutated TSHR as described previously ).
Binding of K1-70 to alkaline phosphatase-labelled TSHR260 (TSHR260-AP)
Briefly, 75 ml start buffer ) and 75 ml human monoclonal antibody diluted in a pool of healthy blood donor (HBD) sera were added to ELISA plate wells coated with the full-length detergent solubilised TSHR and incubated for 30 min at room temperature with shaking (500 shakes per minute). Then the well contents were aspirated, and the wells were washed three times with wash buffer (50 mmol/l NaCl, 20 mmol/l Tris, pH 7 . 8, 1% Triton X-100) followed by the addition of 100 ml TSHR260-AP (diluted in wash buffer containing 0 . 2 g/l MgCl 2 . 6H 2 O and 2 g/l BSA; Rees ). After incubation for 30 min at room temperature with shaking (500 shakes per minute), the wells were emptied, washed three times followed by the addition of 100 ml p-nitrophenyl phosphate (pNpp) substrate (Europa Bioproducts Ltd, Ely, Cambridge UK), and the plate was incubated in the darkness for 45 min. The reaction was stopped by the addition of 50 ml of 1 mol/l NaOH, and the absorbance was read at 405 nm.
Results
Crystal structure of K1-70 Fab residues in the interface, and 41 . 9% are polar (Sanders et al. 2004) . The combining region of the K1-70 antigen-binding site ( Fig. 1) is a highly irregular surface dominated by acidic patches on one side and basic patches on the other side. The acidic patches are centred on D27B (CDR1 LC), D50 (CDR2 LC), D92 (CDR3 LC), D31 (CDR1 HC), D54 and D56 (CDR2 HC) and D96 (CDR3 HC). The basic patches are centred on residues K53 and R54 (CDR2 LC), R94 (CDR3 LC), R58 (CDR2 HC) and R101 (CDR3 HC), and outside the variable domain region K66 LC creates a basic patch. The surface of K1-70 Fab also contains aromatic residues from both the variable regions and residues located close to them (14 residues in total; Fig. 1 ). The surface of the combining region contains a cavity at the centre surrounded mostly by aromatic residues and one charged residue D50 LC. Furthermore, the inside of the cavity is lined by aromatic residues.
In comparison, the surface of the thyroid-stimulating human monoclonal autoantibody (M22) antigenbinding site is also highly charged with acidic patches on one side and basic patches on the other side ( Fig. 1 ; Sanders et al. 2004) .
Crystal structure of the TSHR260-K1-70 Fab complex
The structure of the TSHR260-K1-70 Fab complex was solved to 1 . 9 Å resolution ( Fig. 2A) , and the crystallographic analysis is summarised in Supplementary Table 2, see section on supplementary data given at the end of this article.
The structure of TSHR260 solved from the TSHR260-K1-70 Fab complex is similar to that previously determined from the TSHR260-M22 Fab complex (2 . 55 Å resolution; Sanders et al. 2007a) . A comparison of these two TSHR260 structures shows a root mean square deviation (rmsd) on all C a atoms of only 0 . 51 Å , with the highest deviation of 2 . 42 Å found in the C a atom of H248.
P SANDERS and others . TSHR complex with blocking autoantibody As shown in Fig. 2 and described previously (Sanders et al. 2007a) , TSHR260 has the shape of a slightly curved helical tube constructed from leucine-rich repeat motifs. It has opposed concave and convex surfaces, with an eleven-stranded b-sheet located on the concave surface (ten parallel strands, one per repeat and an anti-parallel strand at the N-terminus). The inner surface of the tube is lined with hydrophobic residues. The concave surface of TSHR260 is formed from an untwisted b-sheet ( Fig. 2A) , and its convex surface presents eight small strands (two residues each) forming two 3-stranded b-sheets and one 2-stranded b-sheet ( Fig. 2A ). There are five glycosylation sites (N77, N99, N113, N177 and N198) located on the convex surface, and all are glycosylated, although the sugars are too disordered to model with confidence at position N113. The structure of TSHR260 shows a nonbonded cysteine at residue 176, which is located in the convex surface but with its side chain placed within the hydrophobic core preventing possible disulphide bonding.
The N-terminal cysteines (C31 and C41) in the TSHR sequence are disulphide bonded. The new structure of TSHR260 solved at 1 . 9 Å shows residues C24, S25, S26, P27, P28 and C29 (Fig. 2B ), while there was no electron density for these residues in the TSHR260-M22 Fab complex solved at 2 . 55 Å (Sanders et al. 2007a ).
The new TSHR260 crystal structure provides therefore details of disulphide bonding arrangements at the TSHR N-terminus and shows disulphide bonds between the 1st and 2nd cysteines (C24 and C29) and between the 3rd and 4th cysteines (C31 and C41; Fig. 2B ).
Interactions in the TSHR260-K1-70 Fab complex K1-70 Fab binds to the concave surface of the TSHR260 and is positioned more N-terminally than the M22 Fab (Sanders et al. 2007a) . Also, K1-70 Fab is bound at an approximate rotation of 1558 on the TSHR260 with respect to the position of M22 Fab, and the orientation of the K1-70 and M22 Fab HCs and LCs are opposite ( The highest deviation for a backbone C a atom is 1 . 29 Å observed for LC G16. In addition, only six of the bound K1-70 Fab residue side chains deviate by more than 3 Å from their positions in unbound K1-70 Fab (LC residues V19, R54 and T80, and HC residues Q3, N76 and R101). TSHR complex with blocking autoantibody . P SANDERS and others 85
All of the glycosylation sites on the TSHR are distant from the K1-70 Fab-binding interface (Fig. 2) . A total of 2565 Å 2 of solvent ASA is buried in the K1-70-TSHR interface, 731 Å 2 in the interaction with K1-70 HC and 622 Å 2 in the interaction with the LC. The interactions between TSHR260 and K1-70 Fab in the complex are a mixture of an extensive hydrogen bonding and salt bridge network (25 hydrogen bonds and salt bridges), 19 water-mediated hydrogen bonds, 11 polar interactions and 19 hydrophobic contacts (Table 1 and Fig. 4 ). There are 24 TSHR260 residues that form direct interactions with K1-70 Fab, and an additional four residues interact through water molecules. Furthermore, there are 12 K1-70 LC residues and 15 HC residues that interact directly with TSHR260 and an additional three LC residues that interact through water molecules. In particular, TSHR K58 is hydrogen bonded to three K1-70 residues (D31 HC, N32 HC and D96 HC), and the K1-70 residue D96 HC is hydrogen bonded to two TSHR residues (R38 and K58). In addition, some TSHR260 residues are involved in strong van der Waals interactions with K1-70, in particular TSHR R80 with an interaction surface of 101 . 5 Table 2 ).
The high resolution (1 . 9 Å ) of the TSHR260-K1-70
Fab complex and the availability of TSHR residues 24-29 in the structure (these were not present in the TSHR260-M22 complex (Sanders et al. 2007a) ) provide new details of the structure of the TSHR N-terminus and reveal that the electrostatic surface potential is negatively charged (Fig. 4D ). This is different from the assessment of the electrostatic potential distribution in the structure solved at 2 . 55 Å . The difference is due to disorder in this region of the TSHR260-M22 structure, while the TSHR260-K1-70 structure shows more detail. The electrostatic surface potential of the TSHR260 concave surface and the K1-70 antigen-binding surface is polarised in terms of charge distribution. The surface distribution of charged residues on K1-70 is complementary to that of TSHR260, with the negatively charged surface of the TSHR260 interacting with the positively charged surface of K1-70 and the positively charged surface of TSHR260 interacting with the negatively charged surface of K1-70 (Fig. 4D ). TSHR D203 is the last residue involved in chargecharge interactions in the TSHR260-K1-70 Fab complex interacting with K1-70 LC R94. The TSHR260 C-terminus is not involved in interactions with the K1-70 Fab ( Fig. 2A ). There are a number of electrostatic interactions in the TSHR260-K1-70 complex, and these are detailed in Table 3 . TSHR R109 produces the strongest accumulated electrostatic interactions with K1-70, whereas K1-70 D31 HC and D50 LC produce the strongest accumulated electrostatic interactions with the TSHR (Table 3) .
Effects of mutations in the TSHR and in K1-70 Fab
We analysed the effects of different amino acid mutations in the TSHR extracellular domain on the ability of K1-70 IgG to block pTSH-induced stimulation of cAMP production in CHO cells expressing the mutated TSHR (Table 4) . Mutation of TSHR residues D43, R80, T104, H105, K129, F130, F134, D151, Q235, K250, E251, R255, T257 and W258 to alanine showed no significant effect (compared with wild-type TSHR) on stimulation of cAMP production by TSH or the TSH antagonist activity of K1-70 IgG. Furthermore, K1-70 binds strongly to TSHR260-AP in the bridge ELISA showing a similar dose-dependent response as the thyroid-stimulating monoclonal autoantibody M22.
K1-70 and M22 IgG at 10 ng/ml gave an OD of 0 . 038 and 0 . 035 respectively (compared with 0 . 00 for HBD pool only), this increased to 0 . 993 and 1 . 045 at 500 ng/ml and a maximum of 1 . 416 and 1 . 532 at 100 mg/ml respectively. However, when full-length TSHR containing the R255D mutation was coated on the ELISA plate wells, K1-70 binding at 100 ng/ml was not significantly reduced (90% of WT TSHR binding), while M22 IgG binding was reduced to 13% of WT TSHR binding.
In the case of TSHR mutations that affected TSH stimulation of cAMP production, i.e. TSHR E107A, E157A, D160A, Y185A, D203A, Y206A, K209A and D232A, no significant effect on the TSH antagonist activity of K1-70 IgG was found. One mutation TSHR E178A caused a slight decrease in activity for both TSH stimulation of cAMP production and inhibition of TSH stimulation by K1-70 (!100-80%). In contrast, the TSHR mutations (K58A, I60A, E61A, Y82A, R109A and K183A) showed an absence or a decrease in TSH antagonist activity of K1-70, while TSH stimulation of cAMP production in the mutated TSHR was similar to that in the wild-type TSHR. Analysis of the interactions of these six residues in the TSHR-K1-70 complex showed that all six interacted with K1-70. In particular, K58, Y82 and R109 are involved in 7 out of the 25 hydrogen bonds and salt bridges present in the structure (Table 1) , while K183 produces a watermediated hydrogen bond with Y99 of the K1-70 HC. Also R109 and K183 are involved in non-hydrogen bonding polar interactions with R58 HC and L95 LC respectively, and I60, E61, Y82 and R109 form hydrophobic contacts (Table 1 ). R109 and K58 are involved in strong van der Waals interactions in the complex (Table 2 ) and form ion pairs with the K1-70 HC D54, D56 and D96 (Table 3) . In contrast, some TSHR amino acids that had no effect on the antagonist activity of K1-70 are involved in interactions within the complex. For example, TSHR R80 forms two salt bridges with K1-70 D50 LC, two water-mediated hydrogen bonds with Y99 HC, a nonhydrogen bonding polar interaction with N100 HC, a strong van der Waals interaction and two ion pair interactions with D50 LC. This shows that the absence of a detectable effect of a mutation in the TSHR on the actions of K1-70 on TSH stimulation does not necessarily indicate that there are no interactions involving this residue. In particular, a mutation may not show any effect if other interactions with the TSHR are not disrupted or are strong enough to compensate for the mutation (Lo Conte et al. 1999 ).
Wild-type and mutated K1-70 rFab preparations (N32A HC, R94D LC, W97A HC, Y99A HC and N100A HC) were expressed in Escherichia coli, and their activity was compared to the native K1-70 Fab produced by digestion of hybridoma K1-70 IgG. The activity of the K1-70 rFab showed a good agreement with the activity of the native Fab for inhibition of TSHbiotin binding and for inhibition of TSH-induced stimulation of cAMP production in CHO cells expressing the TSHR (Fig. 5A) .
Western blotting showed that WT and mutated K1-70 rFab preparations contained !5% smaller cleavage products, and the results of the Easy-Titre (HCL) IgG assay showed that WT and mutated K1-70 rFabs were expressed at a similar level (3 . 7-6 . 0 mg/ml). We compared the activity of K1-70 rFab in E. coli culture supernatant (concentration of rFab measured in the Pierce Easy-Titre Human IgG assay kit) to the activity of purified K1-70 rFab (concentration measured by OD 280 ) using inhibition of TSH-biotin binding to the TSHR, and they were in good agreement (data not shown).
Mutation of K1-70 HC W97A and HC N100A greatly reduced the ability of K1-70 to inhibit TSH binding to TSHR-coated ELISA plate wells, i.e. 11 . 0 and 13 . 8% inhibition respectively at 0 . 1 mg/ml (compared with 93 . 6% by WT), and 17 . 4 and 37 . 8% respectively at 1 mg/ml (compared with 97 . 2% for WT; Fig. 5B ). K1-70 mutations LC R94D, HC Y99A and HC N32A also had an effect giving 62 . 0, 55 . 2 and 71 . 7% inhibition of TSH binding at 0 . 1 mg/ml respectively compared with 93 . 6% in the case of WT (Fig. 5B) .
The five K1-70 Fab mutations HC N100A, HC W97A, LC R94D, HC Y99A and HC N32A resulted in complete P55   S56   T104  R80  Q55  H105  D36  T56  E35  R38  Y82 K58  160  S84  K42  E61 N-ter C-ter The side chain of TSHR residue TSHR R250 is absent in the crystal structure and was modelled prior to generating the electrostatic surface potential of the TSHR LRD.
abolition of the ability to inhibit TSH-induced stimulation of cAMP production giving 0-1 . 9% inhibition at 1 mg/ml compared with 75 . 6% with WT K1-70 Fab (Fig. 5C ). All five residues were observed to be involved in interactions with the TSHR in the crystal structure. Mutation of K1-70 HC W97 had the greatest effect with the ability of the mutant (1 mg/ml) to inhibit TSH binding to the receptor being !20% inhibition (compared with over 90% inhibition of TSH binding with wild-type K1-70) and with no effect on TSHinduced cAMP production being demonstrable (compared with over 70% blocking of TSH-induced cAMP stimulation with wild-type K1-70; Fig. 5B and C).
In the crystal structure, K1-70 HC W97 is involved in a hydrogen bond with TSHR E107, hydrophobic contacts with I60, Y82, S84, E107 and R109, and has strong van der Waals interactions (Table 2) . HC N100 forms a hydrogen bond with TSHR Y82, a water-mediated bond with T56 and a non-hydrogen bonding polar interaction with R80.
Comparison of TSHR-K1-70 Fab, TSHR-M22 Fab and TSHR-TSH complexes

Analysis of the TSHR260-K1-70 Fab, TSHR260-M22 Fab (Sanders et al. 2007a) crystal structures and the TSH-TSHR comparative model (Nú ñez Miguel et al.
2008) allowed a comparison of the binding arrangements within the complexes (Table 5) . As described previously, binding of the human thyroid-stimulating autoantibody M22 mimics the binding of TSH to the TSHR (Nú ñez Miguel et al. 2009 ). The M22 LC mimics the binding of the TSHb chain as both interact with the 1st, 2nd, 4th, 6th, 7th, 8th, 9th and 10th repeats of TSHR260. The M22 HC mimics the binding of the TSHa chain and interacts with residues from the 1st through to the 7th repeat (Table 5 ). In contrast, the K1-70 LC interacts with the 1st through to the 8th repeat, and the HC with the 1st through to the 6th repeat. Consequently, K1-70 does not mimic either the interactions of TSH or M22 binding to the TSHR (Table 5) .
A comparison of interactions in the interfaces of the three complexes demonstrates the increased number of stronger interactions with the TSHR (salt bridges and hydrogen bonds) in the case of K1-70 and M22 compared with the TSHR-TSH complex (25, 22 and 7 hydrogen bonds and salt bridges respectively; Table 5 and Fig. 6 ). The amino acid residues on the concave surface of the TSHR leucine-rich domain (LRD) that interact with TSH in a comparative model (Nú ñez Miguel et al. 2008) , the thyroid-stimulating autoantibody M22 in the crystal structure (Sanders et al. 2007a) and the TSHR blocking autoantibody K1-70 in the crystal structure are detailed in Fig. 6 . There are 24, 25 and 21 residues on the TSHR260 that interact with K1-70, M22 and TSH respectively (Fig. 6) . Although the binding sites of the three ligands on the TSHR concave surface overlap extensively, the actual contact of amino acids differ. There are 16 amino acids that interact with both K1-70 and M22, 12 amino acids that interact with both K1-70 and TSH, and 13 amino acids that interact with both M22 and TSH. Furthermore, ten TSHR amino acids R38, K58, R80, H105, R109, N110, F130, F153, I155 and E157 interact with all three ligands (Fig. 6 ).
Discussion
The availability of the crystal structure of K1-70 Fab (unbound) allowed us to compare the antigen-binding surfaces of this autoantibody with TSH-blocking (antagonist) activity and an autoantibody with thyroidstimulating (agonist) activity (M22; Sanders et al. 2003 Sanders et al. , 2004 . Both the K1-70 and M22 antigen-binding regions are rich in aromatic residues, and statistical analysis (Padlan 1990 ) has shown that tyrosines are three times more likely to be found in CDRs than in the frameworks of variable domains. The electrostatic surface potentials of both K1-70 and M22 TSHR-binding regions (Fig. 1) show highly irregular surfaces dominated by basic patches on one side and acidic patches on the other, although the distribution of the acidic and basic patches is virtually opposite for the two Fabs. In the case of M22, the negatively charged surface patches are formed predominantly by the LC residues, while on the Table 2 Van der Waals interactions in the TSHR260-K1-70 complex. Van der Waals interactions were calculated as the accessible surface area (ASA) difference, for every amino acid, between the uncomplexed and complexed proteins. The ASA was calculated using the Lee and Richards algorithm developed by Richmond (Lee & Richards 1971 , Richmond 1984 surface of K1-70, the negatively charged residues are from the HC. The positively charged residues on the surface of M22 are from the HC, whereas in the case of K1-70, they are from the LC (Fig. 1 ). These observations are consistent with the important role for chargecharge interactions for binding of TSHR autoantibodies to the TSHR observed experimentally (Rees Smith et al. 1988) . The crystal structure of the TSHR in complex with K1-70 that we describe provides details, at the molecular level, of how a human autoantibody that blocks TSH (and thyroid-stimulating autoantibody) stimulation interacts with the TSHR. Furthermore, the interactions of the TSHR with the blocking autoantibody (K1-70) can be compared with the interactions of the TSHR with the thyroid-stimulating autoantibody (M22; Sanders et al. 2007a,b) .
A comparison of the TSHR260 structure when in complex with K1-70 or M22 shows an rmsd on all C a atoms between the structures of only 0 . 51 Å confirming the original solved structure of the TSHR LRD (Sanders et al. 2007a) . Furthermore, the conformation of the TSHR260 structure shows no significant change between the complex with the blocking monoclonal antibody K1-70 and the complex with the stimulating monoclonal antibody M22. This observation suggests that the first step in the process of TSHR activation by stimulating antibodies (such as M22), i.e. ligand binding, does not involve a direct conformational change of the TSHR LRD, and how the binding of M22 (or other TSHR-activating ligands) causes receptor activation is not clear at present. It may be that initial binding to the TSHR LRD induces changes in the hinge region between the LRD and transmembrane domain (TMD). Then this conformational change could cause activation of the TMD , Mizutori et al. 2008 . Crystal structures of the complete TSHR extracellular domain in complex with M22 and in complex with K1-70 should provide key insights into the mechanism of activation.
In the asymmetric unit of the crystals, there was only one complex consisting of one molecule of TSHR260 The higher (1 . 9 Å ) resolution of the TSHR260-K1-70 structure provided details of the disulphide bond arrangements at the N-terminus of the TSHR for the first time (Fig. 2B) . Disulphide bonds are present between the 1st and 2nd cysteines (C24 and C29) and between the 3rd and 4th cysteines (C31 and C41). Thus, N-terminal cysteine disulphide bonding arrangements in the TSHR are different to that observed in the case of the FSHR crystal structure, where the 1st and 3rd cysteines (C18 and C25) and the 2nd and 4th cysteines (C23 and C32) are disulphide bonded (Fan & Hendrickson 2005) . The TSHR has a three amino acid insertion between TSHR C31 and C41 when compared with the FSHR sequence, and consequently bonding between C29 and C41 of the TSHR would be entropically less favourable. Based on TSHR mutagenesis studies reported previously (Chen et al. 2001) , it was proposed that C41 was paired to either C29 or C31, but our crystal structure now provides molecular level detail of the cysteine pairing at the N-terminus of the TSHR including C41 paired to C31. In the crystal structure, K1-70 shows no interaction with the extreme N-terminus of the TSHR LRD, which contains the bonded cysteines. Analysis of the interaction of M22 with the TSHR (using the TSHR LRD structure from the complex solved at 1 . 9 Å ) also showed that there were no M22 interactions involving the extreme N-terminal region of the TSHR LRD. These observations suggest that the TSHR region containing the four disulphide-bonded cysteines does not have a major role in TSHR autoantibody binding and most likely acts as a protective N-terminal cap aiding stability, preventing degradation and keeping the correct conformation of the receptor. This is not consistent with previous studies, which have concluded that the TSHR N-terminal region is part of a highly conformational epitope for thyroid-stimulating autoantibodies (Chen et al. 2001 , Chazenbalk et al. 2004 .
The crystal structure of the complex shows that the K1-70 Fab clasps the concave surface of the TSHR LRD in a similar way to M22 Fab but is in approximately the opposite orientation (i.e. rotated by w1558 on the TSHR helical tube axis; Fig. 3 ). However, K1-70 binds more N-terminal on the TSHR interacting with an extensive surface of the receptor between amino acid D36 and D203, while the binding site of M22 extends further towards the C-terminus and spans the region between TSHR amino acids D36 and N256 (Fig. 3) . The concave surface of the TSHR that interacts with K1-70 is extensive (DASA 2565 . 4 Å 2 ) and is greater than that typically observed for an antibody-antigen interface ( Jones & Thornton 1996 , Lo Conte et al. 1999 . This observation together with the presence of a large number of hydrogen bonds, salt bridges and van der Waals interactions in the interface reflects the high binding affinity of K1-70 for the TSHR. Similar types and levels of interaction are observed for M22 (Sanders et al. 2007a) . In contrast, there are only seven hydrogen bonds and salt bridges in the TSHR260-TSH complex (comparative model Nú ñ ez Miguel et al. 2008) compared with 25 and 22 in the complex of TSHR260 with K1-70 or M22 respectively, and this reflects the 
a Relative effects of TSHR mutations were expressed as a percentage of activity observed with wild type: CCCCC, 100% wild-type activity;
differences in binding affinity of these three ligands to the TSHR.
Comparison of the structures of K1-70 Fab unbound and bound to the TSHR260 indicates that there is essentially no movement in the atoms of K1-70 residues upon binding to the TSHR, which is consistent with a 'lock and key' mode of binding ( Supplementary  Figure 1) . This was also observed in the case of M22 binding to the TSHR (Sanders et al. 2007a) , and consequently, loss of free energy through induction of a conformational change in either K1-70 or M22 does not occur during binding, and this is also consistent with the observed high affinity of the autoantibodyreceptor interaction (McLachlan & Rapoport 1996 , Sanders et al. 2003 , Morganthaler et al. 2007 , Thorpe & Brooks 2007 , Evans et al. 2010 . In contrast to autoantibody binding to the TSHR, considerable conformational changes occur in FSH on binding to the FSH receptor (Fan & Hendrickson 2005) .
Results from TSH binding and cAMP stimulation assays using mutated TSHR or K1-70 Fab provided experimental evidence confirming interactions observed in the crystal structure. Mutations of different TSHR residues that showed strong interactions in the structure influenced K1-70 activity, indicating that the binding arrangements in the complex reflect the interactions of K1-70 with intact, functionally active TSHR at least in vitro, and it is most likely that similar interactions take place when the TSHR and K1-70 combine in vivo.
However, due to the large interfaces of the interacting surfaces of all three ligands (K1-70, M22 and TSH; 2565, 2514 and 2533 Å 2 respectively) with the TSHR, mutation of some interacting residues may not show an effect on binding and/or biological activity (Lo Conte et al. 1999) . For example, TSHR R80 forms several interactions with K1-70 in the complex, but mutation of this residue does not affect K1-70 activity. This is also the case for the mutation of TSHR E251 to alanine , Chen et al. 2010 , which interacts with TSH K44b in the TSH-TSHR comparative model (Nú ñez Miguel et al. 2008) . The salt bridge formed between TSHR E251 and TSH K44b would not be formed in the case of TSHR E251A mutation; however, as this interaction is on the periphery of the interface, the mutation would be unlikely to affect TSH Final concentration of pTSH was 3 ng/ml and gave 76 . 5 G7 . 2 pmol/ml cAMP production in the absence of K1-70 binding and stimulating activities , Chen et al. 2010 . Mutation studies ) identified TSHR R255 as important for the activity of the stimulating autoantibody M22 and patient serumstimulating autoantibodies. However, mutation of TSHR R255 did not affect the TSH antagonist (blocking) activity of K1-70 and has also been reported to be unimportant for the antagonist activity of patient serum autoantibodies . Furthermore, TSHR R255A has no effect on the antagonist activities of the mouse MAb-B2 (Sanders et al. 2005 and the human autoantibody 5C9 ; both with TSH and TSHR autoantibody antagonist activity). In addition, a bridge-type ELISA using TSHR260-AP and TSHR containing R255D mutation can distinguish between the blocking-type monoclonal autoantibody K1-70, which binds to the mutated TSHR, and the stimulating-type monoclonal autoantibody M22, which shows drastically reduced binding compared with the WT TSHR. In the crystal structure, K1-70 Fab does not interact with TSHR R255, and this is in agreement with the experimental studies described in this study and reported previously ). In contrast, TSHR C-terminal patches are involved in electrostatic interactions with thyroid-stimulating autoantibody M22, and R255 is the most C-terminal TSHR260 residue showing charge-charge interactions with M22 LC D60 (Sanders et al. 2007a) .
The exact location of the binding sites for blocking autoantibodies and stimulating autoantibodies on the TSHR molecule has been controversial. Experimental evidence from our laboratory ) and other laboratories (Nagayama et al. 1991 , Rapoport et al. 1998 , Morganthaler et al. 2003 suggests that the epitopes for both types of autoantibodies overlap extensively. In contrast, other reports based on studies with TSHR chimeras concluded that the major binding sites for thyroid-stimulating autoantibodies were located at the N-terminus of the TSHR amino acids 9-165 (Tahara et al. 1991 , Kosugi et al. 1993 , Kim et al. 1996 , Minich & Loos 2000 , Kung et al. 2001 , Minich et al. 2004 , while the epitopes of blocking-type autoantibodies were more towards the TSHR C-terminus (aa 261-370; Tahara et al. 1997 , Minich & Loos 2000 , Kung et al. 2001 . However, the binding arrangements observed in the crystal structure of the TSHR complexed with a blocking-type autoantibody (K1-70) and a stimulating-type autoantibody (M22) clearly show that the binding sites of the two antibodies overlap considerably with K1-70 forming strong interactions with TSHR260 (aa 22-260), even though the previously suggested important blocking antibody epitope (aa 261-370) , Minich & Loos 2000 , Kung et al. 2001 , Loos et al. 2007 ) is missing entirely. Furthermore, both K1-70 and M22 bind strongly in ELISAs based on TSHR260 (Rees ). However, there has been one report (Schwarz-Lauer et al. 2002) in which the TSHR-blocking activity of one patient serum could not be absorbed by purified TSHR289 (aa 22-289), even though the blocking antibodies in a different serum and all the stimulating antibodies studied were absorbed. This could indicate that occasional patient autoantibodies with blocking activity might bind outside the TSHR260 region. However, in a detailed study of the interaction of over 50 patient serum TSHR autoantibodies with TSHR260, all sera were found to interact strongly with this receptor preparation (Rees ). In addition, five sera in which blocking activity was established and five sera in which stimulating activity was established bound strongly to TSHR260. A comparison of the interactions between the TSHR and the TSHR autoantibodies K1-70 and M22 and the hormone TSH was carried out using the respective crystal structures and a comparative model of the TSHR-TSH complex (Sanders et al. 2007a , Nú ñez Miguel et al. 2008 . TSHR autoantibodies with different biological activities interact with the same region of the TSHR (the concave surface of the TSHR LRD) as TSH itself. Thus, the crystal structures provide further evidence for the overlap of the binding sites for TSHR autoantibodies and TSH observed in experimental studies (Rees Smith et al. 1988 , Rapoport et al. 1998 , 2002 , Morganthaler et al. 2003 , Costagliola et al. 2004 , Latif et al. 2009 ). Furthermore, the binding arrangements in the three complexes show important differences in the types of interactions present. In particular, interactions of K1-70 and M22 with the TSHR involve a greater number of strong interactions (hydrogen bonds and salt bridges) than in the case of TSH-TSHR binding. Also the interactions between FSH and FSHR in the crystal structure of the complex involve only six hydrogen bonds and salt bridges (Fan & Hendrickson 2005 , Nú ñez Miguel et al. 2008 ). Thus, TSH or FSH binding to their respective receptors favours hydrophobic interactions, while binding of autoantibodies to the TSHR depends on stronger electrostatic interactions. The differences observed in the interactions in the complexes of the TSHR with TSH and with autoantibodies may reflect differences in how these complexes evolved. From an evolutionary perspective, it would be expected that hormone-receptor interactions have undergone evolutionary optimisations over a very long time that would include a trade-off between specificity of binding and effective biological function. In contrast, antibody-antigen interactions are subject to selection principally driven by binding affinity in addition to binding specificity (Jones & Thornton 1996 , Lo Conte et al. 1999 , Thorpe & Brooks 2007 .
The crystal structures also showed that although M22 and K1-70 both bind to the concave surface of TSHR260 with considerable overlap, there are important differences. K1-70 interacts less with the C-terminus than TSH or M22. Furthermore, K1-70 HC and LC interactions with the TSHR LRD do not mimic the interactions of TSHa and TSHb chains, while the interactions of M22 HC and LC do (Núñez Miguel et al. 2008) . These arrangements most likely reflect the differences in the biological activity of the three ligands, and the observation of molecular mimicry between TSH and M22 (Núñez Miguel et al. 2008) but not between TSH and K1-70 provides a new perspective on the evolution of autoimmune responses in Graves' disease (Bork et al. 1993 , Sanders et al. 2007a , Núñez Miguel et al. 2009 ).
Irrespective of the differences in the type of interactions and the regions on the TSHR LRD concave surface involved in binding to M22, all three ligands form important interactions with the same ten TSHR residues (Fig. 6 ). This observation may be helpful in further understanding the molecular basis of binding between the TSHR and ligands with different biological activities and may lead to the development of new therapies for autoimmune diseases involving the TSHR. Overall, the availability of high resolution crystal structures of the TSHR in complex with blocking-type and stimulating-type human monoclonal autoantibodies provides a foundation for developing new strategies to understand and control TSHR activation and the autoimmune response to the TSHR.
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